The usefulness of cardiac-specific plasma protein biomarkers such as b-type natriuretic peptide (BNP), N-terminal pro-b-type natriuretic peptide (NT-proBNP), and cystinosin (cTns) in the diagnosis of cardiomyopathy is questioned because they may not be sufficient for early detection or better risk stratification of genetic diseases [79], whereas the use of other alternatives, such as circulating miRNAs, has been increasing in the past few years [80]. The gene discussed is CTNS; the disease is hereditary disease.